Christopher J. Sweeney
Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer.
Overview
Christopher Sweeney (University of Adelaide; formerly Dana-Farber) was principal investigator of CHAARTED, the ECOG trial showing early docetaxel with androgen deprivation adds more than a year of survival in high-volume metastatic hormone-sensitive prostate cancer, and co-led ENZAMET (enzalutamide) with ANZUP. His work established treatment intensification at diagnosis as the standard approach. He now directs an immunogenomics institute in South Australia.
Pages like this
not linked directly; found by shared links- PersonMatthew R. Smith
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tags prostate, trialist.
- PersonAndrew J. Armstrong
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tags prostate, trialist.
- PersonKim N. Chi
Shares Androgen receptor, Prostate cancer and the tags prostate, trialist.
- PersonAnthony V. D'Amico
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
- PersonMaha Hussain
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag prostate.
- PersonA. Oliver Sartor
Shares Prostate cancer and the tags prostate, trialist.
- ProductFlutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer.
- ProductNilutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer.